Egypt now makes about 91% of the medicines its people use, and its regulator wants the rest. The Egyptian Drug Authority suspends imports once a local equivalent exists, is targeting the 50 APIs the country imports most, and fast-tracks approvals for plants that make for export. For multinationals, API suppliers and CDMOs, Egypt is becoming a market you serve from inside.
Egypt localization and Manufacturing for Export: latest updates
- Oct 25, 2026: EDA chairman Ali El-Ghamrawy met East Pharma’s chief executive Philippe Haas to discuss expanding local manufacturing and technology transfer.
- Sep 15, 2026: The Pharma Export Council set a target of about $1.6 billion in exports for 2026, up from $1.3 billion in 2025, after EDA joined a mutual recognition framework with seven other African regulators.
- Jul 27, 2026: Egypt opened a $100 million EIPICO plant that uses genetically modified cells to make proteins for APIs, a first for the Middle East.
- Jun 15, 2026: El-Ghamrawy set out EDA’s strategy to 2030, with localization and exports among its five pillars.
Egypt localization and Manufacturing for Export at a glance
| Region | Egypt |
| Instruments | EDA import substitution for products with local equivalents; API localization program; Manufacturing for Export framework; Investment and Export Incentives Guide; National Drug Policy 2026–2030 |
| Legal status | In force and applied by EDA |
| Key dates | Local equivalents list published January 13, 2026; $3 billion export target by 2030 |
| Most exposed | Multinationals importing into Egypt, API suppliers in India and China, Egyptian manufacturers and CDMOs with export capacity |
| Official source | Egyptian Drug Authority |
| PharmaSource Score | 135 (rank 34) Impact 5, Reach 3, Likelihood 9 Download the PharmaSource Regulatory Radar |
What Egypt’s localization and Manufacturing for Export policies are
Egypt’s market reached about EGP 422 billion ($8.48 billion) in 2025, up 37% on 2024. A dollar shortage in 2024 left patients without imported medicines, and the government answered with policy that treats local production as health security. EDA, the regulator, pulls five levers:
- Import substitution: Once a local company develops an equivalent, EDA can cancel the foreign product’s registration or suspend its imports. Its January 2026 list names the most important products localized this way.
- API localization: EDA targets the 50 most heavily imported APIs, nearly 78% of human-medicine API imports. A wider plan covers about 400 APIs across 30 therapeutic categories.
- Manufacturing for Export: A fast-track route for products made in Egypt for foreign markets, which EDA says has more than halved approval times.
- Incentives: EDA’s Investment and Export Incentives Guide offers fast-track registration and localized pricing incentives.
- Recognition: EDA holds WHO Maturity Level 3, and its mutual recognition framework with Ghana, Nigeria, Rwanda, Senegal, South Africa, Tanzania and Zimbabwe speeds registration of Egyptian products in those markets.
Where Egypt’s localization drive stands
- 2016 to 2026: Local production rose from an estimated 80% to 85% of consumption to about 91%, from more than 179 factories and 986 production lines.
- 2023 to 2025: EDA supported localization of 155 APIs used in 234 finished products.
- Dec 2024: EVA Pharma and Eli Lilly began making long-acting insulin glargine in Egypt.
- Jan 13, 2026: EDA published its list of products with local equivalents.
- 2026: EDA adopted a National Drug Policy for 2026 to 2030 that names local manufacturing and exports as priorities.
- 2030 targets: $3 billion in exports, including $1.34 billion to Africa, and 94% self-sufficiency.
What Egypt’s localization policies mean for manufacturing and outsourcing
The finished-dose base is large; the chemistry underneath it is thin. Egypt has only five factories specializing in pharmaceutical raw materials, and Arab API’s chairman Ahmed Kilani said in January that Egypt imports over 90% of its raw materials. That gap shapes who wins:
- Multinationals selling into Egypt: An imported product can lose its market once a local equivalent appears. Technology transfer to a local partner keeps it in: Sandoz and SEDICO are localizing five cancer medicines, and Bayer has partnered with Minapharm to make and export from Egypt.
- Egyptian contract manufacturers: Local firms are leasing production lines to overseas companies, and pharma is among the sectors that rely most on contract manufacturing. Opella runs its Egyptian business through a dual-sourcing contract manufacturing model.
- API suppliers in India and China: Egypt still needs their volume today. Over time, the top-50 program targets exactly the molecules they sell most, and EDA has not published the full list.
- Biologics and plasma: Grifols has invested €280 million in Egypt and plans €180 million more from 2026 to 2029, though its plasma products are still made in Spain. The new EIPICO plant brings recombinant protein work onshore.
- Sponsors supplying Africa: Faster export approvals and mutual recognition make Egyptian sites a route into African markets with smaller regulators.
For outsourcing leaders, the practical step is to check which imported products in Egypt now have, or could soon have, a local equivalent, and to line up a local manufacturing or licensing partner before EDA acts on them.
Why supporters back Egypt’s localization drive
“Cutting regulatory approval times by more than half through fast-track pathways.”
Ali El-Ghamrawy, chairman, Egyptian Drug Authority, on Manufacturing for Export (Business Monthly)
- Supply security: Local plants kept chronic medicines on shelves when foreign currency ran short. EDA says local manufacturing now covers 92% to 94% of demand for essential and chronic medicines.
- Foreign currency: Each localized product cuts the import bill. AmCham Egypt reports that localization replaced 208 imported drugs that had cost more than $732 million a year.
- Export growth: Exports reached about $1.3 billion in 2025, up from $1.079 billion in 2024, and the 2026 target is $1.6 billion to $1.7 billion.
- A regional hub: WHO Maturity Level 3 and mutual recognition give Egyptian approvals weight across Africa, where few countries make their own medicines.
Criticisms of Egypt’s localization drive
“Should not be measured simply by the number of locally manufactured products.”
Muhammad Nouh, R&D general manager, EIPICO, on localization (Arab Finance)
- Import dependence moves upstream: More finished-product capacity does not end reliance on imported inputs, and API made in Egypt at higher cost raises costs for drugmakers and the health system.
- Patient trust: During the 2024 shortages, many patients refused local alternatives and hoarded imported brands. Patients with conditions such as thalassemia still report shortages of imported medicines.
- Price controls: Manufacturers say official prices lag costs. The pound weakened from LE 30 to LE 50 against the dollar while most inputs are priced in foreign currency.
- Opaque targets: EDA has not published the full list of 50 priority APIs or their import values, which makes investment planning harder for suppliers.
What’s next for Egypt’s localization drive
- More local equivalents lists: EDA will add products as local makers develop them, with no fixed schedule.
- API projects: Watch which of the top 50 APIs reach commercial production, and whether EDA publishes the list.
- Grifols complex: The first phase of its industrial complex was due to open in October 2026, and Grifols targets collection capacity of up to 3 million liters of plasma a year by 2029.
- Exports: Whether 2026 exports reach the $1.6 billion target will show if Manufacturing for Export is working.
- Our score: The policy scores 135 (rank 34). Likelihood is 9 because EDA already applies the lists. Impact is 5 because import suspensions force local sourcing, and Reach stays at 3 because the rules bite only on products sold in Egypt.
Related articles
- Japan PMD Act Amendment: Drug Supply Becomes a Legal Duty as Tokyo Funds Domestic Capacity
- Generics Tariffs and the API Reserve: Washington’s Two Levers on Generic Supply
- US-India Trade Framework: Zero Tariffs Promised, a 100% Generics Tariff Looming
- China’s Drug Administration Law Regulations: Segmented Manufacturing, MAH Duties and CDMO Oversight